Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds witin the methods of the invention. The present invention further provides cells obtainable by the methods of the invention.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

Abstract: The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention. Liver disease affects more than 500 million people worldwide. Organ transplantation is the gold standard for treatment of liver failure, but organ shortages are acute.

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.

Abstract: The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal.

Abstract: The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention. Liver disease affects more than 500 million people worldwide. Organ transplantation is the gold standard for treatment of liver failure, but organ shortages are acute.

Abstract: The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal.

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable ester, salt, prodrug or metabolite thereof;

Abstract: Disclosed is a peelable checklist notepad, comprising a plurality of tear away strips. The strips are arranged in layers of connected sheets, wherein each sheet provides a plurality of strips connected by separation lines for recording a top-down list of items. Each strip allows a user to write a particular task or item reminder for later reference. The backside of each strip comprises an adhesive surface, which connects the sheet layers together and allows individual strips to be removed and placed onto another surface for item reminder purposes. Each strip is removed by separating it along its boundary and further peeling it back from its adhered position against an underlying replacement strip. The underlying strip then replaces the removed sheet with a vacant location to record a checklist or reminder item.

Abstract: Systems and methods for processing commercial financial transactions are provided. In one aspect, a method for processing a commercial financial transaction between a customer and a merchant is provided. The method includes approving a customer for receiving a financing package for engaging in the commercial financial transaction with a merchant, and issuing the financing package to the customer from the originator, wherein the financing package includes a check having a plurality of security features and a security agreement between the customer and the originator.

Abstract: Systems and methods for processing commercial financial transactions are provided. In one aspect, a method for processing a commercial financial transaction between a customer and a merchant is provided. The method includes approving a customer for receiving a financing package for engaging in the commercial financial transaction with a merchant, and issuing the financing package to the customer from the originator, wherein the financing package includes a check having a plurality of security features and a security agreement between the customer and the originator.

Abstract: The present invention is directed to an assay system, PAM (Pathway Assay Matrix) for screening drug to determine whether they are effective for treating or preventing a disease or disorder. This assay system takes into account that many diseases involve complex pathways, and measures the effect of a particular drug on the multiple nodes within the disease pathway of a particular disease or disorder.

Abstract: The present invention is directed to an assay system, PAM (Pathway Assay Matrix) for screening drug to determine whether they are effective for treating or preventing a disease or disorder. This assay system takes into account that many diseases involve complex pathways, and measures the effect of a particular drug on the multiple nodes within the disease pathway of a particular disease or disorder.